Avsnitt
-
On this episode of the Diabetes Update Podcast, Dr. Lawrence Leiter and Dr. Beth Abramson discuss the clinical perspectives from endocrinology and cardiology when reducing low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins in patients.
-
What is Continuous Glucose Monitoring and how do we leverage data from these devices for patients with diabetes? On this episode of the Diabetes Update Podcast, Dr. Akshay Jain and Dr. Jeff Habert discuss how Time in Range is a powerful measurement in clinical practice that can provide valuable insights beyond A1C alone.
-
Saknas det avsnitt?
-
In this new Diabetes Update 2022 podcast topic ‘Management of Type I Diabetes in Pregnancy’, we are joined by Dr Amish Parikh who is a staff internist and endocrinologist at Trillium Health Partners, Ontario with his patient Kristen McLellan.
In this podcast, Dr Parikh and Kristen review her experience of using insulin pump therapy as a method to manage Type I diabetes optimally throughout her three pregnancies. Dr Parikh discusses the role of preconception care and counselling, benefits of insulin pumps, and the advantages of virtual care monitoring with the diabetes team, allowing smooth adjustment during various phases of both pregnancy and postpartum stages.
This podcast has been supported by educational funding from Insulet.
-
On this episode of Diabetes Update 2022 podcast series titled, ‘Incorporating novel cardiovascular (CV) risk reduction strategies for diabetes patients: where icosapent ethyl (IPE) fits into our practice’, we welcome Dr Peter Lin, a family physician and Director of Primary Care Initiatives at the Canadian Heart Research Group. He is joined by Dr Jeremy Gilbert, who is an endocrinologist and associate professor at the Sunnybrook Health Sciences Centre.
In this episode, our guests discuss the concurrent triglyceride lowering management alongside LDL lowering management in high-risk patients with cardiovascular disease, as outlined in the 2021 Canadian Dyslipidemia guidelines, and the incremental benefits reported at the REDUCE-IT trial for icosapent ethyl (IPE), the first non-LDL focused lipid therapy, as an adjunct therapy. Identifying candidate patients for IPE, and the role of multiple healthcare providers in patient management are topics covered in this program.
This program was made possible through funding from HLS Therapeutics.
-
On this episode of the Diabetes Update 2022 podcast series titled ‘Let’s Be Friends: a collaborative conversation between endocrinology and cardiology’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Anil Gupta, cardiologist and medical director at the CCU and Clinical Cardiology Trillium Health partner. He is also a partner at the Mississauga Clinical Research Centre.
In this conversation, our guests discuss the different perspectives and considerations endocrinologists and cardiologists have when starting on antihyperglycemic therapy. How do cardiology and endocrinology work together? Where do the lines blur with shared patient care and how can we better communicate with each other to improve patient outcomes?
This program was made possible through funding from Boehringer-Ingelheim and Eli Lilly
-
On this episode of the Diabetes Update 2022 podcast series, we welcome Dr Peter Lin, a family physician, and Director of Primary Care Initiatives at the Canadian Heart Research Group. Also joining us is Dr James Kim, a general practitioner and steering committee member of the Diabetes Canada Clinical Practice Guideline.
A safe and proper insulin injection technique is globally recommended to improve blood glucose control. Sadly, most patients receive minimal training in injection techniques. In this episode, our guests discuss what patients need to know about effective and safe injection technique, the impact of needle size and angle of insertion, poor site rotation, advice regarding needles reuse, and resultant impact on patient HbA1c levels. Although the drug is important, the proper delivery of the drug is equally important.
This program was made possible through funding from Becton Dickinson.
-
On this episode of the Diabetes Update 2022 podcast series titled ‘Stroke in Diabetes’, we are pleased to welcome Dr. Ron Goldenberg, consultant endocrinologist affiliated with North York General Hospital in Toronto, and LMC Diabetes and Endocrinology in Thornhill. We also welcome Dr Tess Fitzpatrick, a stroke neurologist, and a clinical stroke fellow at Sunnybrook Health Sciences Centre in Toronto.
In this conversation, our guests discuss the pathophysiology and contributing factors leading up to stroke in patients with diabetes, as well as the Canadian Stroke Best Practice Guidelines for early screening, recognition, management, and prevention of stroke. Additionally, the episode discusses the importance of a comprehensive management approach to diabetes stroke prevention, including A1C control, cholesterol management, lifestyle modifications, and the role of GLP-1 RAs with proven stroke reduction benefit independent of patients' baseline A1C levels in managing multi-morbid cases.
This program was made possible through funding from Lilly.
-
On this episode of the Diabetes Update 2022 podcast series titled ‘What are we missing in patients with CKD and T2D?’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Phil McFarlane, clinical investigator in the Division of Nephrology at St. Michael’s Hospital in Toronto, and an Assistant Professor at the University of Toronto.
In this conversation, our guests discuss what is meant by chronic kidney disease in diabetes, diagnostic methods, and the four pillars of CKD management indicated by the Diabetes Canada Guidelines. The guests also explore the results and efficacy of Finerenone, a new class three generation aldosterone agonist in improving and preventing CKD outcomes in patients with a broad range of kidney function, considering the FIGARO and FIDELIO trials. Finally, the guests discuss the use of SGLT2is with or without finerenone, and potential additional cardiorenal protective benefits obtained from both drugs.
This program was made possible through funding from Bayer.
-
In episode number 5 of the Diabetes Update 2021 podcast series, we are honored to welcome back Dr. Alice Cheng, endocrinologist from University of Toronto, who will be speaking about new basal insulins and hypoglycemia. As basal insulins have evolved over time, Dr. Cheng makes us consider, how do they compare? The next generation of basal insulin analogs brings significant improvements upon the previous generations. Dr. Cheng concludes by encouraging healthcare professionals to consider which of their patients are best suited for this treatment method, and how to best guide patients.
This program was made possible through funding from Sanofi.
-
In episode 6, we are joined by Dr. Ronald Goldenberg, endocrinologist at LMC Diabetes & Endocrinology in Vaughan, Ontario, and Dr. Jeffrey Habert, family physician and assistant professor at University of Toronto. They dig into the benefits of fixed ratio therapeutic combinations and how to best initiate them for their patients with diabetes, as well as discuss the available agents in Canada.
This program was made possible through funding from Sanofi.
-
In episode 4, Dr. Atul Verma, Director of the Heart Rhythm Program at Southlake Regional Health Centre and associate professor at University of Toronto discusses managing atrial fibrillation in diabetes care. As patients with diabetes are at risk of developing atrial fibrillation, Dr. Verma gives us insights on the use of novel oral anticoagulants (NOACs). He discusses the potential benefit of this treatment method such as reducing adverse effects including major limb events and the potentially preserving renal function. For patients with diabetes, what is the likelihood they develop atrial fibrillation? Listen to find out. The answer may surprise you!
This program was made possible through funding from Bayer.
-
In Episode 3 of the Diabetes Update Congress Podcast, we are joined by Dr. Alice Cheng, endocrinologist from University of Toronto, accompanied by Dr. George Thanassoulis, cardiologist from McGill University and Co-Chair of the 2021 Canadian Cardiovascular Society Dyslipidemia guidelines. Their discussion highlights the new areas of focus in the guidelines, including recommendations on the preventative care of women with hypertensive disorders of pregnancy, the use of new lipid parameters for screening and the introduction of new therapies.
This program was made possible through funding from HLS Therapeutics.
-
In episode 2, Dr. Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre and Ms. Lori Berard, consultant in diabetes management and clinical research operations, discuss recent evidence that demonstrate that improving injection technique can help reduce A1c up to 1%. They discuss how improving injection technique could have a greater benefit compared to other agents that may be costly for the patient. Have you wondered how Canadian practices match up to current progress in this area? Listen to find out.
Visit www.fitfordiabetes.com for more information.
This program was made available through funding from Becton Dickinson.
-
In Episode 1, Professor Naveed Sattar, honorary consultant in metabolic medicine at the Glasgow Royal Infirmary, will discuss the increasing prevalence of heart failure in diabetes. Dr. Sattar discusses the future of heart failure management with therapies such as SGLT2 inhibitors, and the need to consider treatment strategies for the intersection of heart failure and diabetes in future practice. Professor Sattar concludes this podcast by urging healthcare professionals to be aware of the signs of heart failure in their patients and to advocate for a new set of guidelines that will mitigate the risks.
This program was made available through funding from BI-Lilly Alliance.